Vancomycin IV Bags Recalled for Lack of Sterility Assurance
Central Admixture Pharmacy Services is recalling 4,824 bags of vancomycin IV medication nationwide due to inadequate validation of sterilization processes. The manufacturer cannot confirm proper sterility.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of an injectable medication without validated sterility assurance. While no illnesses or injuries have been reported, this is a risk-of-harm product where the lack of sterilization validation for IV medications presents significant potential for serious infection.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 4,824 bags of vancomycin 1.25 g/250 mL IV solution due to lack of assurance of sterility. The recalled product was distributed nationwide.
The recall stems from inadequate validation of decontamination cycles used in manufacturing. Without validated decontamination procedures, the manufacturer cannot confirm that the product meets sterility requirements necessary for injectable medications that enter the bloodstream directly.
No illnesses or injuries have been reported. However, intravenous medications lacking sterility assurance present a significant potential risk of bacterial contamination and infection.
The recalled product
- Product
- vancomycin 1.25 g/250 mL added to dextrose 5%, 5 mg/mL, IV Bag, Rx only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Phoenix AZ 85043, NDC: 72196-6073-1
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Injectable / IV Solution
- Hazard
- contamination
- sterility-failure
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 36-245562
- Exp. 8/2/2023
- 36-254425
- Exp. 9/5/2023
- 36-255129
- Exp. 9/6/2023
- 36-238965
- Exp. 7/10/2023
- 36-256041
- Exp. 9/11/2023
- 36-241129
- 36-241130
- Exp. 7/19/2023
- 36-241438
- Exp. 7/20/2023
- 36-242703
- Exp. 7/26/2023
- 36-243163
- 36-243164
- Exp. 7/27/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27